BTK and ovarian carcinoma: In addition, we also showed that it might be an actionable target: in fact, using in vitro (cell lines) and ex vivo (cells freshly dissociated from patient-derived xenografts and patient-derived cancer) experimental systems we found that BTK inhibitors strongly affected proliferation and survival of ovarian carcinoma cells (Conconi et al., 2018).